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ABSTRACT 
The aim of the present study was to investigate the hepatotoxic effects of accidental intrave-
nous diethylene glycol (DEG) poisoning in patients with liver disease.  
Clinical manifestations were recorded and liver function tests were carried out for 64 patients 
with liver disease who had been accidentally treated intravenously with DEG. Comparisons 
were made between the poisoned and non-poisoned groups.  
Of the 64 cases with preexisting liver disease, 15 cases (23.4 %) developed toxic presenta-
tions after exposure to DEG. All cases were men. Twelve of the 15 poisoned patients (80 %) 
died within seven days. The intravenous administration of DEG resulted in only mild liver 
function impairment. Gender (p = 0.039) and the severity of jaundice prior to DEG admin-
istration were risk factors related to the occurrence of toxin-induced renal failure (p < 0.006).  
The results suggest that DEG may worsen liver damage in patients with preexisting liver dis-
ease. However, our study demonstrated only mild, transient alterations in patients’ baseline 
liver functions. Severe liver damage secondary to DEG was only occasionally seen in patients 
with concomitant renal failure. 
 
Keywords: diethylene glycol, hepatotoxicity, drug-induced liver disease, underlying liver 
diseases 
 
Abbreviations: Diethylene glycol – DEG，Alanine transaminase – ALT, Aspartate transam-
inase – AST, Gamma glutamyl transpeptidase – GGT，Alkaline phosphatase – ALP, Total 
bilirubin – TB, Prothrombin time – PT, Prothrombin time activity – PTA, Serum cholinester-
ase – CHE，Serum albumin – ALB, Blood urea nitrogen – BUN，Blood creatinine – Cr, 
White blood cell – WBC, Standard deviation – SD 
 
 
INTRODUCTION 
The liver is the most important detoxi-
fying organ in the body and plays a critical 
role in the metabolism of drugs and toxins. 
The majority of drugs and toxins can be 
cleared from the body following hepatic 
biotransformation. However, some drugs 
and toxins or their active metabolites can 
cause liver damage resulting in drug- or 
toxin-induced hepatitis, or even liver fail-
ure. In patients with no preexisting liver 
disease, exposure to toxic substances or 
hepatotoxic drugs leads to the appearance 
of symptoms most commonly within eight 
weeks, and drug or toxin-induced hepatitis 
is not usually difficult to diagnose (Zim-
merman, 2000; Sgro et al., 2002). In pa-
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tients with underlying liver diseases, how-
ever, the diagnosis of drug- or toxin-
induced hepatitis remains challenging as it 
is difficult to distinguish between the natu-
ral course of the existing liver disease and 
additional damage resulting from exposure 
to drugs or toxins. Close monitoring of liv-
er function after toxin exposure is required 
in these cases. 
Diethylene glycol (DEG) is an indus-
trial product commonly used in daily life. 
It is used as a coolant, both lowering the 
freezing point of a solution and elevating 
its boiling point making the solution more 
stable in hot climates. DEG is also used as 
a building block in organic synthesis, e.g., 
in the synthesis of morpholine and 1,4-
dioxane. It is a solvent for nitrocellulose, 
resins, dyes, oils and other organic com-
pounds. It is a humectant (a hydroscopic 
substance) for tobacco, cork, printing ink 
and glue. It can also be found in some hy-
draulic fluids and brake fluids. 
DEG is toxic to humans and animals, 
and can lead to death by renal failure. The 
toxicity of DEG means that its use is strict-
ly regulated in the manufacture of food and 
drugs. The U.S. Code of Federal Regula-
tions allows no more than 0.2 % of DEG in 
polyethylene glycol when the latter is used 
as a food additive. However, DEG is still 
illegally used as counterfeit glycerin in 
some nations and sold internationally as a 
component of cough syrup, toothpaste and 
mouthwash. 
In April 2006, 64 patients with liver 
disease from The Third Affiliated Hospital 
(Guangzhou, China) received armillarisin 
A, a jaundice therapy manufactured by Qi-
qihar No. 2 Pharmaceutical Co. Ltd (Qiqi-
har, China). Fifteen of these patients de-
veloped acute renal failure following ad-
ministration of armillarisin A. Testing by 
the Guangdong Drug Testing Center and 
the National Drug Testing Center of China 
detected high concentrations of DEG. No 
previous cases of DEG poisoning in pa-
tients with underlying liver disease have 
been reported, and the effects of DEG poi-
soning on patients with underlying liver 
disease are therefore unknown. The aim of 
this study was to investigate whether acci-
dental intravenous DEG poisoning led to 
an exacerbation of liver damage in patients 
with underlying hepatic disease. 
 
MATERIALS AND METHODS 
Study subjects 
The study population consisted of 64 
patients with liver disease who were ad-
ministered 10–20 ml of intravenous armil-
larisin A (Qiqihar No. 2 Pharmaceutical 
Co. Ltd., Qiqihar, China), to treat jaundice. 
The armillarisin A was later found to con-
tain 30 % DEG. All patients were treated 
at the Third Affiliated Hospital of Sun Yat-
Sen (Guangzhou, China) between April 19, 
2006 and May 1, 2006. Patients were treat-
ed with armillarisin A once daily for 1–11 
days during this time (see Suppl. Table 1). 
 
Diagnostic criteria  
Based on previous research, a 3–point 
criteria for the clinical diagnosis of DEG 
poisoning was followed. The criteria speci-
fied: (1) an obvious history of DEG expo-
sure (intravenous or oral), (2) the appear-
ance of oliguria or anuria that are charac-
teristic of acute renal impairment or renal 
failure following DEG exposure (i.e., typi-
cally within two weeks of the final dose), 
and (3) the exclusion of other factors that 
cause acute renal impairment or renal fail-
ure. Other clinical manifestations and la-
boratory tests including the presence of 
metabolic acidosis, neurological impair-
ment symptoms (predominantly a multifo-
cal peripheral neuropathy) and histopatho-
logical characteristics of renal damage, 
such as acute tubular necrosis and tubu-
lointerstitial nephritis, were carried out in 
some cases to assist in the diagnosis of 
DEG poisoning. Fifteen cases of DEG poi-
soning were identified by a group of ex-
perts in the field according to the criteria 
specified above. 
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Method of detection  
Liver function and serum biochemical 
assays including: alanine transaminase 
[ALT], aspartate transaminase [AST], 
gamma glutamyl transpeptidase [GGT] or 
alkaline phosphatase [ALP], total bilirubin 
[TB], prothrombin time [PT], prothrombin 
time activity [PTA], serum cholinesterase 
[CHE] serum albumin [ALB], blood urea 
nitrogen [BUN] and blood creatinine [Cr], 
were performed using BS-200 (Mindray 
Company, Shenzhen, Guangdong Province, 
China), a fully automated biochemistry 
analyzer. The DEG content of armillarisin 
A solutions was determined using spectro-
photometry by the Food and Drug Admin-
istration in Guangdong Province (GDFDA; 
China) (Maurer et al., 2001). 
 
Study method 
Clinical manifestations were recorded 
and blood samples were collected before, 
and 1–8 weeks after, the intravenous ad-
ministration of the DEG-contaminated ar-
millarisin a solution (see Suppl. Table 2). 
Based on these results, the 64 patients in-
volved were divided into two groups: poi-
soning or non-poisoning depending on 
whether DEG poisoning was evident. A 
case-control method was subsequently em-
ployed to examine whether DEG exacer-
bated the preexisting liver damage in this 
patient population. 
The relationship between DEG poison-
ing and alterations in liver function were 
analyzed based on the standard diagnostic 
criteria for drug-induced liver damage and 
toxin-induced hepatitis (Bissell et al., 2001; 
Schencker et al., 1999; Tegeder et al., 
1999). Diagnostic standards of acute exac-
erbation of liver function specify that one 
or more of the following clinical signs oc-
cur within 1–8 weeks following DEG ex-
posure: liver function abnormalities (in-
cluding a five-fold elevation of any of the 
following: ALT, AST, GGT or ALP); an 
ALT/ALP ratio >5; elevation of preexist-
ing jaundice, increased PT; development of 
new complications, and improvement or 
recovery following the removal of the tox-
in. 
In this study, the following data were 
recorded for all members of the study pop-
ulation: gender, age, whether poisoning 
had occurred, total dose of DEG inad-
vertently administered, dose concentration 
each time and pre-treatment liver function 
indicators. These data were used for multi-
variable regression analysis to detect the 
risk factors of poisoning. 
 
Statistical analysis  
Statistical analysis was carried out us-
ing the SPSS 13.0 software (2006, Guang-
zhou, China). Measurement data were pre-
sented as means ± standard deviation (SD), 
and comparisons between pre- and post-
poisoning data were performed using non-
parametric multiple correlation sample 
analysis (Friedman test). Wilcoxon rank 
sum test of two independent samples was 
used to compare the accumulated dosage 
of armillarisin A between the poisoned 
group and non-poisoned group. Statistical 
significance was defined as p <0.05. Uni-
factorial chi-squared analysis was used to 
analyze dynamic changes in liver function 
indicators between the poisoning and non-
poisoning group. Enumeration data were 
examined using four-fold table chi-squared 
analysis. Logistic multivariable regression 
analysis was used to analyze factors corre-
lated with the occurrence of poisoning.  
 
RESULTS 
Baseline characteristics 
Of the 64 patients included in this 
study, 15 were female (23.4 %) and 49 
were male (76.6 %). The oldest patient was 
76 years old and the youngest patient was 
five years old (mean: 45.7 ± 1.91). All pa-
tients were diagnosed with chronic liver 
disease, including 14 cases of severe hepa-
titis (21.9 %), 14 cases of cirrhosis result-
ing from hepatitis B (21.9 %), 20 cases of 
severe chronic hepatitis (31.3 %), six cases 
of hepatocellular carcinoma (9.4 %), two 
cases of post-transplantation liver disease 
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(3.1 %), and one case each of Wilson’s 
disease, primary biliary cirrhosis, lym-
phoma-induced liver damage and cholan-
giocarcinoma (1.6 % each). Prior to the 
initiation of intravenous injections of 
DEG-contaminated armillarisin A, chronic 
hepatobiliary tract infections and variable 
degrees of jaundice were present in all cas-
es.  
 
Characteristics of DEG poisoning 
DEG poisoning occurred in 15 of the 
64 patients (23.4 %) and they were all 
male. All DEG poisoned patients devel-
oped oliguric acute renal failure after a la-
tency period of 2–12 days (mean = 5 days) 
after DEG administration. There was no 
significant difference in the accumulated 
dosage of armillarisin A between the poi-
soned group and non-poisoned group (see 
Table 1). Renal failure in patients poisoned 
with DEG can display a wide spectrum of 
liver disease severity, from mild to more 
advanced stages, compared with hepatic 
renal failure patients, who usually display 
severe hepatic disease with higher levels of 
TB, much lower PTA, more frequent asci-
tes and a higher white blood cell (WBC) 
count. In this study, the onset of renal fail-
ure in DEG poisoned patients was more 
acute than in hepatic renal failure. Urinary 
output decreased rapidly and the mean 
progression time from oliguria to anuria 
was only one day. In DEG poisoned pa-
tients, Cr increased rapidly and reached a 
higher level than that in patients with hepa-
to-renal failure. Renal damage was ob-
served by routine urinalysis and ultrasonic 
exams (see Table 2). Percutaneous renal 
biopsies were obtained in two cases and 
each demonstrated acute tubular necrosis.  
In the early periods of poisoning, most 
patients had nonspecific symptoms such as 
abdominal distension, abdominal pain and 
loin pain. Seven of the 15 patients also de-
veloped a low-grade fever. Nine cases had 
nausea and vomiting which were initially 
assumed to be due to worsening of the un-
derlying liver disease. Ten of the 15 pa-
tients developed symptoms of neurological 
system damage, which manifested mainly 
as cranial nerve damage or paralysis. Pe-
ripheral nerves were affected in four cases 
which resulted in limb paralysis and even 
respiratory muscle paralysis. Metabolic 
acidosis developed in the majority of pa-
tients (13/15, 86.7 %). In total, 12 of the 15 
poisoned patients (80 %), equivalent to 
18.7 % of exposed patients, died within 
seven days of exposure to DEG. Of these, 
seven patients died from multiple organ 
dysfunction syndromes, four patients died 
from severe infection and one patient died 
from gastrointestinal hemorrhage. Con-
cerning the three surviving patients inad-
vertently poisoned with DEG, one patient 
received a liver transplant (which presum-
ably played an integral role in patient sur-
vival) and two patients totally recovered. 
 
Liver function dynamic changes 
Liver function indicators were recorded 
from 64 patients for eight weeks following 
the administration of DEG-contaminated 
armillarisin A.Comparisons between pre-
injection and post-injection, and between 
the poisoned and non-poisoned group of 
patients were made. The results revealed 
that the intravenous administration of DEG 
resulted in mild liver function impairment. 
ALT levels were slightly increased at week 
6, TB transiently increased at week 3 
(which lasted less than one week), CHE 
transiently decreased slightly at week 3 
and small fluctuations in ALP occurred 
throughout the period (see Table 3). No 
additional abnormalities were noted. As 
some patients died, some patients im-
proveed and were discharged, we can only 
collect liver functions of different weeks in 
remain patients. Comparisons between pre-
injection and post-injection for the patients 
observed a complete set of data were made. 
The results suggested that there was no 
significant difference in ALT (P=0.248）
and ALP（P=0.107）after the intravenous 
administration of DEG. TB transiently in-
creased at week 3 (see Table 4). 
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Table 1: Comparing the accumulated dosage of armillarisin A between the poisoned group and non-
poisoned group  
Groups n Accumulated dosage (ml) 
(Median) 
Inter-quartile range (ml) 
(P25-P75) 
Poisoned group 15 50.0* 40.0-80.0 
Non-poisoned group 49 70.0 30.0-110.0 
* P=0.768  
 
Table 2: Comparing the basic information and main changes after onset of renal failure between DEG 
poisoning and hepatic renal failure  
Characteristics Poisoning group 
(n=15) 
Hepatic renal failure 
(n=45) 
P 
Gender male 15 (100 %) 41 (91.1 %) 0.55 
Age 
 Median 
 Range 
 
49.23 ± 13.73 
33-76 
 
49.31 ± 11.85 
13-70 
 
0.982 
Diagnosis 
 Liver failure 
 Liver disease 
 without liver failure 
 
7 (46.7 %) 
 
8/15 (53.3 %) 
 
41 (91.1 %) 
 
4 (8.9 %) 
 
0.001 
 
0.001 
Complications 
 Ascites 
 Renal diseases 
 
10 (66.7 %) 
5 (33.3 %) 
 
42/45 (93.3 %) 
6 (13.3 %) 
 
0.028 
0.178 
After renal failure: 
 TB (µmol/L) 
 PTA (%) 
 BUN (mmol/L) 
 Cr (µmol/L) 
 WBC (109/L) 
 Platelet count (109/L) 
 
375.59 ± 260.70 
55.0 ± 25.48 
15.41 ± 7.40 
340.55 ± 151.91 
7.63 ± 2.99 
106.9 ± 50.6 
 
617.07 ± 210.37 
22.18 ± 10.46 
25.10 ± 26.07 
229.60 ± 129.28 
13.47 ± 5.50 
101.32 ± 90.95 
 
0.001 
0.000 
0.026 
0.009 
0.000 
0.983 
Urine routine abnormal* 10 (66.7 %) 2 (4.65 %) 0.000 
Ultrasound exam abnormal* 14 (93.3 %) 3 (6.7 %) 0.000 
Urine routine abnormal*: white blood cell elevation, urine protein positive or cylindruria 
Ultrasound exam abnormal*: signal enhancement of renal parenchyma 
 
 
Table 3: Changes in liver function after administration of DEG  
Time* N Alt (Mean ± SD) N TB (Mean ± SD) N ALP (Mean ± SD) 
0 61 178.98 ± 264.70 61 253.8661 ± 217.89 59 194.53 ± 232.35 
1 58 79.31 ± 61.36 58 247.99 ± 220.79 57 156.44 ± 155.65 
2 40 131.70 ± 428.80 40 270.6663 ± 247.85 40 150.38 ± 127.65 
3 26 60.58 ± 48.18 25 299.61 ± 251.62 25 137.00 ± 136.72 
4 20 70.65 ± 55.33 20 307.06 ± 251.77 20 145.30 ± 133.11 
5 17 80.35 ± 79.69 17 226.59 ± 221.11 17 181.19 ± 167.95 
6 15 69.69 ± 49.45 14 185.75 ± 202.87 14 205.00 ± 206.11 
7 13 64.00 ± 40.65 13 191.42 ± 225.39 12 188.00 ± 117.19 
8 7 63.43 ± 35.06 6 200.97 ± 314.00 7 277.43 ± 206.11 
*weeks after DEG administration 
EXCLI Journal 2012;11:98-107 – ISSN 1611-2156 
Received: December 31, 2011, accepted: March 16, 2012, published: March 20, 2012 
 
103 
Table 4: Changes in liver function after administration of diethylene glycol (for the patients observed a 
complete set of data)  
Time* Alt (Mean ± SD) 
(n=7) 
TB (Mean ± SD) 
(n=6) 
ALP (Mean ± SD) 
(n=7) 
0 130.86 ± 89.77 293.87 ± 177.73 289.57 ± 253.84 
1 76.29 ± 35.16 268.00 ± 180.64 216.57 ± 106.03 
2 70.57 ± 37.34 332.83 ± 272.69 192.00 ± 98.67 
3 67.71 ± 33.47 257.90 ± 239.77 250.29 ± 224.7 
4 86.57 ± 67.91 222.92 ± 213.68 240.14 ± 196.13 
5 110.86 ± 107.96 188.31 ± 186.83 295.29 ± 207.08 
6 73.57 ± 43.35 188.07 ± 231.15 300.71 ± 264.64 
7 78.29 ± 46.40 199.93 ± 182.95 244.24 ± 124.87 
8 63.43 ± 35.06 200.97 ± 314.00 277.43 ± 188.26 
*weeks after DEG administration 
 
Compared with pre-injection levels, 
ALT increased five-fold in two of the 15 
patients in the poisoned group at week 5 
post-injection. AST increased to more than 
five-fold in four patients in the poisoned 
group. Of these, AST levels increased dur-
ing week 1 in three of the four patients 
whereas AST did not increase until week 3 
in the final patient. GGT increased to more 
than five-fold in four patients, but only one 
of these patients was in the poisoned 
group. ALP increased by more than five-
fold in one patient in the non-poisoned 
group (see Table 5). 
Jaundice increased in 24 of the 64 pa-
tients, including seven patients from the 
poisoning group, which was not statisti-
cally significant. PTA decreased in 23 pa-
tients, including nine patients from the poi-
soned group (p < 0.05). Albumin decreased 
in 35 patients, 12 of whom were from the 
poisoned group (p < 0.05). Overall, a 
greater than five-fold increase in a single 
serum biochemistry parameter was noted 
in 11 of the 64 patients, but no patient dis-
played a simultaneous increase of two en-
zymes. Only one patient from the non-
poisoned group experienced a simulta-
neous increased of jaundice, GGT and 
ALP. Decreased PTA and elevation of 
jaundice was observed simultaneously in 
14 patients (five patients were from the 
poisoning group, p > 0.05). 
 
Risk factors of poisoning 
The risk factors of the occurrence of 
DEG-induced renal failure were assessed 
by multivariable regression analysis. The 
results showed gender (p = 0.039) and the 
severity of jaundice prior to DEG admini-
stration were related to the occurrence of 
DEG-induced renal failure (p<0.006). To-
tal dose was not related to the occurrence 
of DEG-induced renal failure (p=0.821). 
No significant correlations between age, 
dose concentration and pre-injection ALT, 
AST, GGT, ALP, PTA and CHE levels, 
were identified.  
 
Table 5: Cases that met the severe liver damage criteria 
Index Poisoning  
group 
No poisoning 
group 
Statistically  
significant 
ALT (increase > 5-fold) 2 0 neg 
AST (increase > 5-fold) 4 0 neg 
GGT (increase > 5-fold) 1 3 neg 
ALP (increase > 5-fold) 0 1 neg 
TB (elevation) 7 17 neg 
PTA (decrease) 9 14 p = 0.04 
ALB (decrease) 12 23 neg 
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DISCUSSION 
Diethylene glycol (DEG) is an organic 
compound with a wide range of applica-
tions. During the past century there have 
been a few incidents of acute DEG poison-
ing. In 1937, ethanol and sugar were re-
placed by DEG in the manufacture of Elix-
ir Sulfanilamide in the United States which 
resulted in 358 cases of poisoning, includ-
ing 107 deaths. In this incident, individuals 
were exposed to DEG via the oral route 
and poisoning was mostly detected in ret-
rospective analysis of renal failure and ep-
idemiological investigations (O'Brien et al., 
1998; Karlson-Stiber and Persson, 1992; 
Hanif et al., 1995). In this report, we de-
scribe patients with preexisting liver dis-
ease who were exposed to a high concen-
tration of DEG after accidental intravenous 
injection. 
DEG itself is nontoxic. Poisoning by 
this compound is a result of the toxicity of 
its metabolites following hepatic and renal 
metabolism. It is currently thought that the 
occurrence of poisoning after DEG expo-
sure depends on endogenous alcohol dehy-
drogenase (ADH) activity. ADH is present 
in the liver, kidneys and gastrointestinal 
tract. If the level of ADH activity is high, 
more active products of DEG metabolism 
are produced, and there is a higher likeli-
hood of developing DEG poisoning. Fol-
lowing the development of renal failure, 
the pharmacodynamics of DEG is corre-
spondingly altered (Heilmair et al., 1993). 
DEG remains detectable in the organs and 
blood in poisoned patients for up to 2–3 
days following the onset of renal failure. 
Therefore, patients with renal failure may 
develop liver function impairment more 
easily, this is confirmed by the results of 
this study. In patients poisoned with DEG, 
two patients developed worsening gastro-
intestinal symptoms, abdominal distension 
and hepatic encephalopathy. Eight weeks 
following the inadvertent intravenous ad-
ministration of DEG, analysis of liver dy-
namic function showed that PTA and ALB 
were decreased in nine and 12 patients, 
respectively.  
Jaundice was a common observation in 
DEG-poisoned patients reported during the 
1937 incident in the United States. In a 
separate group of patients, hepatomegaly 
was more commonly noted in DEG-related 
renal failure than non-DEG-related renal 
failure (53 % and 33 %, respectively) 
(Okuonghae et al., 1992). This finding 
suggests that DEG poisoning may result in 
liver damage in patients without underly-
ing liver disease, and possible manifesta-
tions include hepatomegaly, jaundice, in-
creased GGT and increased ALP (Kawa-
moto et al., 1990). Under normal circum-
stances, the presence of intrinsic liver dis-
ease is often an independent risk factor in 
the development of drug- or toxin-induced 
hepatitis. The results of this study suggest 
that liver disease may have an effect on the 
occurrence of renal failure following DEG 
poisoning as the rate of renal failure was 
related to the severity of jaundice prior to 
administration of DEG.  
In patients with severe liver disease or 
deep jaundice, the ability of hepatocytes to 
synthesize ADH or the liver’s ability to 
excrete DEG was impaired, thereby result-
ing in decreased formation of hepatotoxic 
active metabolites. In turn, a greater pro-
portion of unmetabolized DEG existed, 
which resulted in a higher incidence of re-
nal toxicity. A significant worsening of 
liver disease, however, was not observed in 
patients with underlying liver disease ad-
ministered intravenous DEG. Indeed, liver 
function indicators showed only transient, 
slight or insignificant changes in hepatic 
function, indicating that DEG-induced liv-
er damage is less severe in these patients. 
Toxin-induced liver damage can be di-
vided into three categories: hepatocellular, 
cholestatic and mixed types. Hepatocellu-
lar damage is characterized mainly by in-
creased ALT, AST, GGT and ALP levels. 
ALT and AST are often significantly ele-
vated in hepatocellular toxin-induced liver 
damage, often by more than 100 times the 
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normal level. AST levels greater than 
3000 IU/L have been reported in patients 
with 90 % hepatocellular toxin-induced 
liver damage. In contrast, jaundice is nor-
mally less severe in hepatocellular damage 
compared with cholestatic and mixed types 
of liver damage (Gunawan and Kaplowitz, 
2004; Dufour et al., 2000). Cholestatic liv-
er disease is characterized by elevation of 
jaundice accompanied by increased GGT 
and ALP levels. Moreover, if liver disease 
progresses to liver failure, the clinical 
presentation may manifest as elevated 
jaundice and prolonged PTA. 
In this study, a five-fold increase in a 
single enzyme was observed in 11 patients, 
but a simultaneous increase in two en-
zymes was not noted in any of the 64 pa-
tients. This finding suggests that the risk of 
developing acute cellular toxicity is low in 
patients with liver disease following intra-
venous DEG administration. The absence 
of increased ALT, AST and ALP levels 
was consistent with the results obtained 
from animal studies. In our study, only one 
patient simultaneously developed worsen-
ing jaundice, increased GGT and increased 
ALP. Interestingly, this patient was from 
the non-poisoned group and these findings 
might simply be due to a worsening of the 
patient’s condition. Therefore, most pa-
tients did not match the diagnostic criteria 
for hepatocellular or cholestatic toxin-
induced liver damage. 
Changes in liver function indicators 
within the first eight weeks post-DEG in-
jection were observed in patients with un-
derlying liver disease. These results 
showed that a worsening in liver function 
was not observed in the majority of pa-
tients, and obvious acute increases in ALT, 
AST, GGT and ALP did not occur; the 
proportion of patients who developed con-
current worsening jaundice and decreased 
PTA levels did not increase. Liver function 
prior to and post-DEG administration, and 
the differences in most liver function indi-
cators between the poisoned and non-
poisoned groups were not significant. Only 
a small number of patients developed 
slight increases in ALT, early increases in 
TB and decreases in CHE. Most values 
returned to normal levels rapidly and the 
alterations lasted less than one week. Liver 
function changes may relate to underlying 
liver disease as well as DEG poisoning. 
Whether these changes were secondary to 
progression of underlying liver disease or 
exacerbated by acute DEG poisoning is 
still unclear. Further research is needed to 
establish a standard for the diagnosis of 
toxic liver damage in cases of underlying 
liver disease. We combined dynamic moni-
toring of liver function with identification 
of cases with liver enzymes elevated more 
than five times the normal levels after 
DEG exposure, to detect the hepatic toxic 
effect of DEG on patients with underlying 
liver disease. 
The exacerbation of liver function was 
rare in this study. This finding is incon-
sistent with previous reports in which liver 
damage was observed in patients without 
liver disease following DEG or other toxin 
poisoning. Normally, the incidence of drug 
and toxin poisoning is higher in patients 
with intrinsic liver disease, and the risk of 
developing toxic liver damage relates to 
the severity of liver disease. Also, liver 
damage is often further accelerated follow-
ing drug or toxin poisoning. A number of 
possible reasons for this disparity exists. 
First, exposure via the intravenous route 
may result in different degrees of toxicity 
or poisoning compared with exposure via 
the oral route. For example, DEG may be 
more deleterious to the liver following oral 
administration. Second, in liver disease, 
especially severe liver disease associated 
with decreased liver enzyme activity, the 
liver’s ability to produce hepatotoxic ac-
tive metabolites is reduced. However, the 
correlation between jaundice severity be-
fore DEG injection and the rate of poison-
ing noted in this study does not support 
this view. Instead, the underlying liver 
damage might increase the excretion of the 
unaltered form of DEG, resulting in an in-
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crease in the occurrence of renal failure. 
Next, the onset of poisoning in patients 
was acute, and disease progression and 
death due to renal failure was rapid. In the 
early stages of poisoning, immediate initia-
tion of dialysis and other hepatoprotective 
treatments may reduce the risk of develop-
ing additional liver function impairment. 
Finally, individual variation in response to 
the administration of DEG may also ex-
plain the differences in poisoning rates. 
Many developing countries lack the 
ability or resources to monitor and prevent 
the occurrence of this type of poisoning 
and underlying liver diseases such as hepa-
titis and alcoholic liver diseases are epi-
demic in many countries. The early detec-
tion of poisoning would allow for treat-
ment by hemodialysis and liver protected 
therapy, possibly increasing the survival 
rate. Therefore further animal experiments, 
especially those including subjects with 
liver disease, are needed to establish the 
metabolism of DEG, the risk of worsening 
liver damage and the type of liver impair-
ment that occurs following DEG exposure.  
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